| 3 | 2 | | *JMB177* 02/27/2025 11:04:58 AM JMB177 |
|---|
| 4 | 3 | | State of Arkansas 1 |
|---|
| 5 | 4 | | 95th General Assembly A Bill 2 |
|---|
| 6 | 5 | | Regular Session, 2025 HOUSE BILL 1619 3 |
|---|
| 7 | 6 | | 4 |
|---|
| 8 | 7 | | By: Representative Gramlich 5 |
|---|
| 9 | 8 | | By: Senator Irvin 6 |
|---|
| 10 | 9 | | 7 |
|---|
| 11 | 10 | | For An Act To Be Entitled 8 |
|---|
| 12 | 11 | | AN ACT TO SET ADMINISTRATION FEES UNDER THE ARKANSAS 9 |
|---|
| 13 | 12 | | MEDICAID PROGRAM FOR IMMUNIZATIONS AND MONOCLONAL 10 |
|---|
| 14 | 13 | | ANTIBODIES FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE; 11 |
|---|
| 15 | 14 | | TO PROVIDE CIVIL IMMUNITY FOR ADMINISTRATION OF 12 |
|---|
| 16 | 15 | | IMMUNIZATIONS AND MONOCLONAL ANTIBODIES FOR 13 |
|---|
| 17 | 16 | | RESPIRATORY SYNCYTICAL VIRUS DISEASE; AND FOR OTHER 14 |
|---|
| 18 | 17 | | PURPOSES. 15 |
|---|
| 19 | 18 | | 16 |
|---|
| 20 | 19 | | 17 |
|---|
| 21 | 20 | | Subtitle 18 |
|---|
| 22 | 21 | | TO SET ADMINISTRATION FEES UNDER THE 19 |
|---|
| 23 | 22 | | ARKANSAS MEDICAID PROGRAM FOR 20 |
|---|
| 24 | 23 | | IMMUNIZATIONS AND MONOCLONAL ANTIBODIES 21 |
|---|
| 25 | 24 | | FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE; 22 |
|---|
| 26 | 25 | | AND TO PROVIDE CIVIL IMMUNITY. 23 |
|---|
| 27 | 26 | | 24 |
|---|
| 28 | 27 | | BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS: 25 |
|---|
| 29 | 28 | | 26 |
|---|
| 30 | 29 | | SECTION 1. Arkansas Code Title 20, Chapter 77, Subchapter 4, is 27 |
|---|
| 31 | 30 | | amended to add an additional section to read as follows: 28 |
|---|
| 32 | 31 | | 20-77-408. Administrative fees for immunizations and monoclonal 29 |
|---|
| 33 | 32 | | antibodies for respiratory syncytial virus disease — Definition. 30 |
|---|
| 34 | 33 | | (a) As used in this section, "respiratory syncytial virus disease" 31 |
|---|
| 35 | 34 | | means a respiratory infection of the nose, throat, and lungs caused by the 32 |
|---|
| 36 | 35 | | respiratory syncytial virus. 33 |
|---|
| 37 | 36 | | (b) The Arkansas Medicaid Program shall reimburse an administration 34 |
|---|
| 38 | 37 | | fee that is equal to one hundred percent (100%) of the maximum administration 35 |
|---|
| 39 | 38 | | fee of the Vaccines for Children Program for this state for administration of 36 HB1619 |
|---|
| 40 | 39 | | |
|---|
| 41 | 40 | | 2 02/27/2025 11:04:58 AM JMB177 |
|---|
| 42 | 41 | | an immunization or monoclonal antibody used for long -lasting protection from 1 |
|---|
| 43 | 42 | | respiratory syncytial virus disease in infants and toddlers, regardless of 2 |
|---|
| 44 | 43 | | the category in which the beneficiary receiving the immunization or 3 |
|---|
| 45 | 44 | | monoclonal antibody is enrolled, including without limitation the Medicaid 4 |
|---|
| 46 | 45 | | Provider-Led Organized Care Act, § 20 -77-2701 et seq. 5 |
|---|
| 47 | 46 | | (c) This section does not require a hospital licensed under § 20 -9-213 6 |
|---|
| 48 | 47 | | to provide any new or additional service related to administering the 7 |
|---|
| 49 | 48 | | immunization or monoclonal antibody used for long -lasting protection from 8 |
|---|
| 50 | 49 | | respiratory syncytial virus disease in infants and toddlers. 9 |
|---|
| 51 | 50 | | (d) The Department of Human Services shall apply for any federal 10 |
|---|
| 52 | 51 | | waiver, Medicaid state plan amendment, or other authority necessary to 11 |
|---|
| 53 | 52 | | implement this section. 12 |
|---|
| 54 | 53 | | 13 |
|---|
| 55 | 54 | | SECTION 2. Arkansas Code Title 16, Chapter 114, Subchapter 2, is 14 |
|---|
| 56 | 55 | | amended to add an additional section to read as follows: 15 |
|---|
| 57 | 56 | | 16-114-214. Immunity related to administration of immunization or 16 |
|---|
| 58 | 57 | | monoclonal antibody used for long -lasting protection from respiratory 17 |
|---|
| 59 | 58 | | syncytial virus disease — Definition. 18 |
|---|
| 60 | 59 | | (a) As used in this section, "respiratory syncytial virus disease" 19 |
|---|
| 61 | 60 | | means a respiratory infection of the nose, throat, and lungs caused by the 20 |
|---|
| 62 | 61 | | respiratory syncytial virus. 21 |
|---|
| 63 | 62 | | (b)(1) A person or entity that prescribes, dispenses, administers, or 22 |
|---|
| 64 | 63 | | is otherwise involved in the administration of an immunization or monoclonal 23 |
|---|
| 65 | 64 | | antibody used for long -lasting protection from respiratory syncytial virus 24 |
|---|
| 66 | 65 | | disease in infants and toddlers to an eligible patient is immune from civil 25 |
|---|
| 67 | 66 | | liability. 26 |
|---|
| 68 | 67 | | (2) A person or entity is not immune from civil liability for 27 |
|---|
| 69 | 68 | | actions taken during the administration of an immunization or monoclonal 28 |
|---|
| 70 | 69 | | antibody that: 29 |
|---|
| 71 | 70 | | (A) Are grossly negligent, reckless, or willful; or 30 |
|---|
| 72 | 71 | | (B) Are not taken in good faith and with reasonable care. 31 |
|---|
| 73 | 72 | | 32 |
|---|
| 74 | 73 | | 33 |
|---|